Current Cancer Drug Targets
Volume 20, 11 Issues, 2020
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
  |
In the current Pandemic scenario, all articles related to Coronavirus will be processed on a quick track basis, to ensure timely review and publication of much needed research
Contents
Current Cancer Drug Targets, Volume 16 - Number 4
Editorial Open Access
Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin
, 16(4): 288 - 304Zhipeng Zou, Juan Chen, Jun Yang and Xiaochun Bai
DOI: 10.2174/1568009616666151113120830
Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin
A New Therapeutic Era in GCB and ABC Diffuse Large B-cell Lymphom a Molecular Subtypes: A Cell of Origin-Driven Review
, 16(4): 305 - 322Jose D. Sandoval-Sus, Julio Chavez and Samir Dalia
DOI: 10.2174/1568009615666151030102539
A New Therapeutic Era in GCB and ABC Diffuse Large B-cell Lymphom a Molecular Subtypes: A Cell of Origin-Driven Review
New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia
, 16(4): 323 - 345Rui Huang, Qian Kang, Huimin Liu and Yuhua Li
DOI: 10.2174/1568009615666150921141004
New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia
Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
, 16(4): 346 - 356Xue-Qing Hu, Yang Sun, Eric Lau, Ming Zhao and Shi-Bing Su
DOI: 10.2174/1568009616666151207105851
Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
Development of Linker-Conjugated Nanosize Lipid Vesicles: A Strategy for Cell Selective Treatment in Breast Cancer
, 16(4): 357 - 372Niladri Shekhar Dey, Biswajit Mukherjee, Ruma Maji and Bhabani Sankar Satapathy
DOI: 10.2174/1568009616666151106120606
Development of Linker-Conjugated Nanosize Lipid Vesicles: A Strategy for Cell Selective Treatment in Breast Cancer
Epigallocatechin-3-gallate Increases RXRγ-mediated Pro-apoptotic and Anti-invasive Effects in Gastrointestinal Cancer Cell Lines
, 16(4): 373 - 385Alessio Papi, Marzia Govoni, Carmen Ciavarella, Enzo Spisni, Marina Orlandi and Fulvia Farabegoli
DOI: 10.2174/1568009615666150817120931
Epigallocatechin-3-gallate Increases RXRγ-mediated Pro-apoptotic and Anti-invasive Effects in Gastrointestinal Cancer Cell Lines
Editor-in-Chief
Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
(USA)
View Full Editorial Board
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
View Full Editorial Board
About the Journal
For Authors
For Librarians & Readers
Quick Links
Journal History
Current Cancer Drug Targets was launched in 2001. Dr. Ruiwen Zhang serves as the Editor-in-Chief of the journal.
Scopus CiteScore Metrics: 2.75
Advertisement
Webmaster Contact: info@benthamscience.net